Member Info for Laura2022

My 400k+ at 5.8p average looking wonderful

Well done to all (Green boxes exempt )

Once 1.25 goes 2p looks quote easy

8p on the ask

:)

Those procrastinating or whining last few days are missing out ;)

Smkrs/86

Also been buying TCF SBTX

Yes

Looks like a tug of war for control of AFRN

86

Also the Directors and other funds too

GSK plc (LSE/NYSE: GSK) today announced that it has entered an agreement to acquire 35Pharma Inc., a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics. The acquisition includes HS235, a potential best-in-class investigational medicine that has completed phase I healthy volunteer clinical trials with studies to start imminently in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).

PH is a progressive, life-shortening disease marked by high blood pressure in the lungs. Early symptoms are breathlessness, fatigue and chest pain leading to heart failure as the disease progresses. It affects approximately 82 million people worldwide across multiple disease forms, yet treatment options remain limited and the five‑year survival rate is only around 50%.1,2 By 2032, the global market for PH therapies is forecast to reach $18 billion, with activin signalling inhibitors expected to account for 50% of this.

Philip Markham Chesterfield: A prominent British businessman and investor. He recently acquired a significant 9.447% stake in GENinCode PLC, a predictive genetics company. He is also a director at Accredo, an FCA-authorised firm.

In the January 21st RNS they talk about c.3mths

Analytical validation

The FDA requested additional CARDIO inCode-Score test information relating to the lab processes used and the measures required to ensure samples are appropriately acquired and results are consistent and accurate when using the test. The Company is preparing this data in line with its FDA discussions and believes the provision of this information will satisfy the FDA requirements.

Very high chance

Sellers replaced by buyers yesterday, not much available on the ask whereas last week it was regularly £50,000

Also, no TR1 sellers as yet and what looks like to those who know more than me that this is a timing issue and maybe an attempt by the rump mgmt to have a reason to get rid of a CEO is was deeply unpopular, paid too highly and seemingly a liability(?)

Croda results in the Life Science section show a growing market after a tough 15mths for pharmaceutical industry due to trump, tariffs , funding issues across whole market

Very interesting read Obsidian

What's your view on this asset given Crodas results today please

With kind permission I've posted your final paragraph

Given AIM’s appetite for binary outcomes, the opacity around volume/value is likely fuelling speculation.

However, until FRP reports:

The existence of Zenakine sales is not equivalent to validated royalty revenue.

Auditor approval does not immunise against later reassessment.

An NDA does not prevent internal forensic scrutiny.

Summary

FRP cannot compel Croda beyond contractual rights.

If audit rights exist, Croda must cooperate.

NDAs virtually always allow disclosure to appointed advisers.

The £0.77m reversal suggests evidential uncertainty, not necessarily wrongdoing.

The outcome will depend entirely on the drafting of the licence agreement.

In corporate disputes, the contract is king — and forensic accountants its rather meticulous courtiers.

If you wish, I can also outline the most likely contractual structures in biotech-licensing agreements and how this typically plays out in practice.

If, as alleged, fraud has been committed, what was the net gain?

I note Mr Tom Winnifrith is now inserting the word ‘allege’ when he cites fraud. Is this an admission he is wrong with his initial assement and will he apologise.

Lead product CARDIO inCode-Score across Europe, the UK, and the United States which will assist the Company to transitioning towards break-even over the medium term.

CVD is the leading cause of death worldwide, responsible for over 17.9 million deaths annually, which equates to approximately 31% of all global deaths (World Health Organisation). With the global annual cost of CVD projected to surpass $1.04 trillion by 2030, the directors believe there is an unmet need to accelerate the adoption of genetic testing as an adjunct to the current standard of care. 

Smkrs

We've done very well on REE from 1.3p

Fully expecting GENI.to be at least 100% higher by March 2026

Global market $1 trillion for GENI products

Nice buy this afternoon

Tr1 holder confirmed today

As for "that poster" aka Gerbil

What a miserable way to spend your adult life ...truly pathetic some people on LSE

Birdman

Very magnaminous

Thanks

Has similar on REE last year at 1.25p (now 3.5p)

And GENI last month at 1p

SBTX was clearly too expensive at 25p but far too cheap at 5p

Hope you have done well too

Kendal

We've had 3 or 4 dubious game players on this BB for last 6 weeks

From January sky news

Sky News has learnt that private equity firms INCLUDING Bridgepoint and Triton Partners are exploring bids for Spire Healthcare Group, which runs nearly 40 of the UK's biggest private hospitals.

Mol

So do you feel its going well .?